AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8
AXL receptor tyrosine kinase (AXL)
CD8(+) T cell
Dendritic cell (DC)
Lung cancer
Tumor microenvironment
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
05 11 2023
05 11 2023
Historique:
received:
10
08
2023
revised:
23
08
2023
accepted:
10
09
2023
medline:
10
10
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
AXL is a member of TAM receptor family and has been highlighted as a potential target for cancer treatment. Accumulating evidence has uncovered the critical role of the AXL signaling pathway in tumor growth, metastasis, and resistance against anti-cancer drugs, as well as its association with cancer immune escape. However, the function of AXL as a manipulator of the immune system in the tumor microenvironment (TME) remains unclear. Therefore, in this study, we investigated the impact of AXL on immune cells in the TME of a syngeneic tumor model using AXL knockout (AXL
Identifiants
pubmed: 37703603
pii: S0006-291X(23)01051-3
doi: 10.1016/j.bbrc.2023.09.021
pii:
doi:
Substances chimiques
Axl Receptor Tyrosine Kinase
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-14Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.